

Johnson & Johnson Innovative Medicine Pipeline

Key Events in 2025*

POTENTIAL APPROVALS US/EU

PLANNED SUBMISSIONS US/EU

POTENTIAL CLINICAL DATA PRESENTATIONS¹

POTENTIAL APPROVALS US/EU		PLANNED SUBMISSIONS US/EU		POTENTIAL CLINICAL DATA PRESENTATIONS ¹			
				Phase III	Phase I/ II		
US EU	SIMPONI (golimumab) Pediatric Ulcerative Colitis (PURSUIT 2)	US EU	nipocalimab Generalized Myasthenia Gravis (Vivacity MG3)	US	TAR-200 (RIS/gemcitabine plus cetrelimab) Non Muscle Invasive Bladder Cancer (SunRISe-1)	US	TAR-200 (RIS/gemcitabine plus cetrelimab) Non Muscle Invasive Bladder Cancer (SunRISe-1)
US	TREMFYA (guselkumab) Ulcerative Colitis Subcutaneous Induction (ASTRO)	✓ US	SPRAVATO (esketamine) Treatment Resistant Depression monotherapy (TRD4005)	US	aticaprant Adjunctive Treatment for Major Depressive Disorder with Anhedonia (Ventura)	US	TREMFYA (guselkumab) Ulcerative Colitis Subcutaneous Induction (ASTRO)
US EU	TREMFYA (guselkumab) Crohn's Disease Subcutaneous Induction (GRAVITI)	US EU	DARZALEX (daratumumab) Smoldering Multiple Myeloma (AQUILA)	US EU	TREMFYA (guselkumab) Psoriatic Arthritis Structural Damage (APEX)	US	TREMFYA (guselkumab) Ulcerative Colitis Subcutaneous Induction (ASTRO)
US	TREMFYA (guselkumab) Pediatric Psoriasis (PROTOSTAR)	US EU	DARZALEX (daratumumab) Frontline multiple myeloma transplant ineligible (CEPHEUS)	US EU	TREMFYA (guselkumab) Pediatric Psoriasis (PROTOSTAR)	US	TREMFYA (guselkumab) Psoriatic Arthritis Structural Damage (APEX)
US EU	TREMFYA (guselkumab) Crohn's Disease (GALAXI)	US EU	RYBREVANT (amivantamab) Subcutaneous (PALOMA-3)	US EU	STELARA (ustekinumab) Pediatric Ulcerative Colitis (UNIFY JR)	US	TREMFYA (guselkumab) Pediatric Psoriasis (PROTOSTAR)
US	TREMFYA (guselkumab) Pediatric Juvenile Psoriatic Arthritis	EU	IMBRUVICA (ibrutinib) Frontline MCL (Triangle)	US	STELARA (ustekinumab) Pediatric Crohn's Disease (UNITI JR)	US	icotrokinra Psoriasis (ICONIC-LEAD, ICONIC-TOTAL)
EU	TREMFYA (guselkumab) Ulcerative Colitis (QUASAR)			US EU	icotrokinra Psoriasis (ICONIC)	US	icotrokinra Psoriasis (ICONIC-Advance1/2)
EU	STELARA (ustekinumab) Pediatric Crohn's Disease (UNITI JR)						icotrokinra Psoriasis (ICONIC-Advance1/2)
							aticaprant Adjunctive Treatment for Major Depressive Disorder with Anhedonia (Ventura 1)
							RPGR Gene Therapy Retinitis Pigmentosa (LUMEOS)

✓ = Achieved

¹ In order to be on key events clinical presentation, data must be presented at a major medical meeting.

*This is not a fully exhaustive list of all pipeline programs and assets. The pipeline includes assets currently progressing through clinical trials as well as those under review by regulatory bodies. Inclusion in the pipeline is based on the current status of these programs and assets and does not guarantee continued investments. This information is as of January 22, 2025 to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information.